Transparency Market Research
(TMR) has published a new report titled, ‘Osteoporosis Drugs Market -
Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’.
According to the report, the global Osteoporosis Drugs market was valued
at US$ 11.5 Bn in 2018 and is projected to
contract at a CAGR of 0.3% from 2019 to 2027.
Request Brochure –
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=133
Overview
·
Osteoporosis is a chronic and life-threatening disease, in which
microstructure of bones is altered due to reduction in bone mass and bone
density. This condition leads to increased bone fragility and threat of bone
cracks and fractures. Thus, osteoporosis is considered life threatening due to
severe injury and associated pain.
·
Elevation in threat of bone cracks and introduction of new drug therapy
classes are the factors that are fuelling the growth of osteoporosis drugs
market. Since there is no distinct substitute available to treat osteoporosis
(such as, surgery), the drugs therapy is an inevitable part of osteoporosis
treatment
·
Growing aging population leads for higher prevalence of osteoporosis
which brings more growth opportunities for osteoporosis drugs market.
·
North America dominated the global osteoporosis drugs market in 2018 and
the trend is anticipated to continue during the forecast period. Higher
osteoporosis incidence & prevalence rate, presence of major companies, and
better diagnosis rate for the diseases are some of the major factors to dive
the market in this region.
Request COVID Analysis on Osteoporosis
Drugs Market –
https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=133
Rise in prevalence
of osteoporosis across the globe to Drive Market
·
Higher incidence & prevalence of osteoporosis across the world is
the major driver for the growth of global osteoporosis market.
·
For instance, according to International Osteoporosis Foundation,
Osteoporosis causes more than 8.9 million fractures annually,
resulting in an osteoporotic fracture every 3 seconds and also it is estimated
to affect 200 million women globally.
·
Moreover growing aging population aged above 50 years are at the
greatest risk of developing osteoporosis and related fractures due to hormonal
changes. So this rise in aging population also fuelling the growth of global
market.
·
Development of novel approaches for the treatment of osteoporosis by new
drugs and increase in awareness among people for the early diagnosis &
treatment are also some of the major factors for the growth of this market.
Request Customization on Osteoporosis Drugs Market Report –
https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=133
Bisphosphonates
Segment to Dominate Market
·
Based on drug class, the global osteoporosis drugs market has been
divided into Bisphosphonates, Calcitonin, RANK Ligand Inhibitors,
Parathyroid Hormone Therapy (PTH), Selective Estrogen Receptor Modulators
(SERMs), Sclerostin Inhibitor, and others.
·
RANK ligand inhibitors dominated the market in 2018 due
to market exclusivity of branded drugs and its efficacy to treat osteoporosis.
However this segment is projected to lose its market share by the end of 2027 due
to patent expiration and generics availability.
·
Bisphosphonates segment is projected to dominate by the end of 2027 to
first mover advantage for this class and extensive prescriptions of
bisphosphonates in osteoporosis treatment.
·
Sclerostin Inhibitor segment is expected to grow with higher CAGR during
the forecast period owing to novel approach for of the drug for osteoporosis
treatment and recent launch of product in 2019.
Buy Osteoporosis Drugs Market Report –
https://www.transparencymarketresearch.com/checkout.php?rep_id=133<ype=S
North America to
Dominate Global Market
·
In terms of region, the global osteoporosis drugs market has been
segmented into North America, Europe, Asia Pacific, Latin America, and Middle
East & Africa.
·
North America accounted for major share of the global osteoporosis drugs
market in 2018, owing to higher prevalence of osteoporosis, recent
approval of drugs in the region, and early diagnosis of disease.
·
For instance, as per International Osteoporosis Foundation, osteoporosis
and low bone mass are currently estimated to be a major public health threat
for almost 44 million U.S. women and men aged 50 and older
·
The Osteoporosis Drugs market in Asia Pacific is anticipated to expand
at a high CAGR from 2019 to 2027. This can be
attributed to growing aging population, higher demand of branded as well as
generic products for osteoporosis, and increased awareness towards diagnosis
& management of osteoporosis, and preference of population towards drugs
with less side-effect.
Competitive
Landscape
·
The global Osteoporosis Drugs market is fragmented in terms of number of
players. Key players in the global market include Eli Lilly and
Company, Pfizer, Inc., Amgen, Inc., Merck & Co., Inc., Radius Health,
Inc. , Novartis AG, Teva Pharmaceutical Industries Ltd., Novo Nordisk A/S, F.
Hoffmann-La Roche Ltd., UCB S.A., Mylan N.V., and Apotex Inc. among
others
The global Osteoporosis Drugs market
has been segmented as follows:
·
Global Osteoporosis Drugs Market, by Drug Class
o Bisphosphonates
o Calcitonin
o RANK Ligand
Inhibitor
o Parathyroid Hormone
Therapy (PTH)
o Selective Estrogen
Receptor Modulators (SERMs)
o Sclerostin
Inhibitor
o Others
·
Global Osteoporosis Drugs Market, by Region
o North America
§ U.S.
§ Canada
o Europe
§ Germany
§ U.K.
§ France
§ Italy
§ Spain
§ Rest of Europe
o Asia Pacific
§ China
§ India
§ Japan
§ Australia & New
Zealand
§ Rest of Asia
Pacific
o Latin America
§ Brazil
§ Mexico
§ Rest of Latin
America
o Middle East &
Africa
§ GCC Countries
§ South Africa
§ Rest of Middle East
& Africa
About Us
Transparency Market Research is a
global market intelligence company, providing global business information
reports and services. Our exclusive blend of quantitative forecasting and
trends analysis provides forward-looking insight for thousands of decision
makers. Our experienced team of analysts, researchers, and consultants, uses
proprietary data sources and various tools and techniques to gather and analyze
information.
Our data repository is continuously
updated and revised by a team of research experts, so that it always reflects
the latest trends and information. With a broad research and analysis
capability, Transparency Market Research employs rigorous primary and secondary
research techniques in developing distinctive data sets and research material
for business reports.
Contact
Transparency Market Research,
90 State Street, Suite 700,
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com/
